Showing results (81-90 of 376) with videos related to
Sort By:
Pageof 38
The Journal of Antimicrobial Chemotherapy|March 16, 2010
The future of antiretroviral therapy: challenges and needsSantiago Moreno, Jose López Aldeguer, José Ramón Arribas, et al.AIDS (London, England)|July 29, 2004
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or lessElena Ferrer, Elena Santamariña, Pere Domingo, et al.Enfermedades Infecciosas Y Microbiologia Clinica|December 25, 2012
[Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain]Erik Smets, Anita J Brogan, Andrew Hill, et al.Antimicrobial Agents and Chemotherapy|March 21, 2012
Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokinesJulieta Díaz-Delfín, Pere Domingo, Maria Gracia Mateo, et al.Antiviral Therapy|July 26, 2005
Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytesM Luisa Rodríguez de la Concepción, Pilar Yubero, Joan C Domingo, et al.Journal of Personalized Medicine|November 27, 2021
Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General PopulationAnna Camps-Vilaró, Silvia Pérez-Fernández, Isaac Subirana, et al.Nature Reviews. Disease Primers|July 4, 2020
Author Correction: HIV and antiretroviral therapy-related fat alterationsJohn R Koethe, Claire Lagathu, Jordan E Lake, et al.Nefrologia|April 28, 2019
Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort studyPere Domingo, Ignacio Suarez-Lozano, Félix Gutierrez, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study)Anthony Lamarca, Nathan Clumeck, Andreas Plettenberg, et al.Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|December 15, 2022
Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in SpainÁngeles Castro, Pilar Díaz, Pere Domingo, et al.Pageof 38